Last reviewed · How we verify
insulin infusion — Competitive Intelligence Brief
marketed
Insulin (recombinant human insulin or insulin analog)
Insulin receptor (INSR)
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
insulin infusion (insulin infusion) — IKFE Institute for Clinical Research and Development. Insulin infusion delivers exogenous insulin directly into the bloodstream to regulate blood glucose by promoting cellular glucose uptake and storage.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| insulin infusion TARGET | insulin infusion | IKFE Institute for Clinical Research and Development | marketed | Insulin (recombinant human insulin or insulin analog) | Insulin receptor (INSR) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Insulin (recombinant human insulin or insulin analog) class)
- IKFE Institute for Clinical Research and Development · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- insulin infusion CI watch — RSS
- insulin infusion CI watch — Atom
- insulin infusion CI watch — JSON
- insulin infusion alone — RSS
- Whole Insulin (recombinant human insulin or insulin analog) class — RSS
Cite this brief
Drug Landscape (2026). insulin infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-infusion. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab